Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Constipation Overview | 9 | 1 |
| Therapeutics Development | 10 | 2 |
| Pipeline Products for Constipation Overview | 10 | 1 |
| Pipeline Products for Constipation Comparative Analysis | 11 | 1 |
| Constipation Therapeutics under Development by Companies | 12 | 2 |
| Constipation Therapeutics under Investigation by Universities/Institutes | 14 | 1 |
| Constipation Pipeline Products Glance | 15 | 3 |
| Late Stage Products | 15 | 1 |
| Clinical Stage Products | 16 | 1 |
| Early Stage Products | 17 | 1 |
| Constipation Products under Development by Companies | 18 | 2 |
| Constipation Products under Investigation by Universities/Institutes | 20 | 1 |
| Constipation Companies Involved in Therapeutics Development | 21 | 20 |
| AlbireoPharma | 21 | 1 |
| Ardelyx, Inc. | 22 | 1 |
| Astellas Pharma Inc. | 23 | 1 |
| Braintree Laboratories, Inc. | 24 | 1 |
| CJ HealthCare Corp. | 25 | 1 |
| EA Pharma Co Ltd | 26 | 1 |
| Ironwood Pharmaceuticals, Inc. | 27 | 1 |
| Kissei Pharmaceutical Co., Ltd. | 28 | 1 |
| Motus Therapeutics Inc | 29 | 1 |
| NGM Biopharmaceuticals, Inc. | 30 | 1 |
| RaQualia Pharma Inc. | 31 | 1 |
| Sanwa Kagaku Kenkyusho Co., Ltd. | 32 | 1 |
| Shire Plc | 33 | 1 |
| SK Biopharmaceuticals Co., Ltd. | 34 | 1 |
| Sucampo Pharmaceuticals, Inc. | 35 | 1 |
| Sumitomo Dainippon Pharma Co., Ltd. | 36 | 1 |
| Synergy Pharmaceuticals, Inc. | 37 | 1 |
| Synthetic Biologics, Inc. | 38 | 1 |
| Torrent Pharmaceuticals Limited | 39 | 1 |
| Yuhan Corporation | 40 | 1 |
| Constipation Therapeutics Assessment | 41 | 9 |
| Assessment by Monotherapy Products | 41 | 1 |
| Assessment by Target | 42 | 2 |
| Assessment by Mechanism of Action | 44 | 2 |
| Assessment by Route of Administration | 46 | 2 |
| Assessment by Molecule Type | 48 | 2 |
| Drug Profiles | 50 | 57 |
| 5-BIOP Drug Profile | 50 | 1 |
| AJG-555 Drug Profile | 51 | 1 |
| ASP-7663 Drug Profile | 52 | 1 |
| BLI-400 Drug Profile | 53 | 1 |
| BLI-801 Drug Profile | 54 | 1 |
| CJ-14199 Drug Profile | 55 | 1 |
| DA-6886 Drug Profile | 56 | 1 |
| DSP-6952 Drug Profile | 57 | 1 |
| elobixibat Drug Profile | 58 | 2 |
| KWA-0711 Drug Profile | 60 | 1 |
| linaclotide Drug Profile | 61 | 7 |
| lovastatin Drug Profile | 68 | 3 |
| lubiprostone Drug Profile | 71 | 8 |
| NGM-282 Drug Profile | 79 | 2 |
| plecanatide Drug Profile | 81 | 7 |
| prucalopride succinate Drug Profile | 88 | 2 |
| prucalopride succinate Drug Profile | 90 | 1 |
| relamorelin Drug Profile | 91 | 5 |
| relenopride hydrochloride Drug Profile | 96 | 1 |
| RQ-00000010 Drug Profile | 97 | 2 |
| SK-1202 Drug Profile | 99 | 1 |
| tenapanor hydrochloride Drug Profile | 100 | 5 |
| Transilon Drug Profile | 105 | 1 |
| YH-12852 Drug Profile | 106 | 1 |
| Constipation Dormant Projects | 107 | 1 |
| Constipation Product Development Milestones | 108 | 12 |
| Featured News &Press Releases | 108 | 1 |
| Jun 09, 2016: Ironwood and Allergan Announce Supplemental New Drug Application for 72 mcg Linaclotide in Chronic Idiopathic Constipation Has Been Accepted for FDA Review | 108 | 1 |
| May 24, 2016: Synergy Pharmaceuticals Presents New In Vitro Data Showing the pH-Dependent Activity of Plecanatide Replicates That of Naturally Occurring GI Peptide Uroguanylin | 108 | 1 |
| May 23, 2016: Synthetic Biologics Announces Detailed Data from Two SYN-010 Phase 2 Clinical Trials for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) | 108 | 2 |
| May 22, 2016: Synergy Pharmaceuticals Presents New Plecanatide Phase 3 Data in Chronic Idiopathic Constipation at Digestive Disease Week | 110 | 1 |
| May 21, 2016: Synergy Pharmaceuticals Presents Additional Phase 3 Plecanatide Data in Chronic Idiopathic Constipation at Digestive Disease Week | 110 | 2 |
| May 17, 2016: Ironwood Pharmaceuticals to Present Linaclotide Data at Digestive Disease Week 2016 | 112 | 1 |
| May 17, 2016: Synthetic Biologics to Host Post-DDW 2016 Conference Call to Recap SYN-010 Phase 2 Clinical Trial Results for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) | 113 | 1 |
| May 16, 2016: Synergy Pharmaceuticals to Present New Plecanatide Data at Digestive Disease Week 2016 | 113 | 1 |
| May 11, 2016: Isaac J. Bright, MD, Joins Synthetic Biologics as Vice President, Corporate Development | 114 | 1 |
| Apr 19, 2016: Synergy Pharmaceuticals Announces Acceptance of New Drug Application for Plecanatide, a Novel Uroguanylin Analog, in Chronic Idiopathic Constipation | 115 | 1 |
| Feb 29, 2016: Video Alert: Updated 2016 Direct-to-Consumer Awareness Campaign Available for LINZESS (linaclotide) | 115 | 1 |
| Feb 17, 2016: Synthetic Biologics Announces the Allowance of Key U.S. Patent Covering SYN-010 intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation | 115 | 1 |
| Jan 29, 2016: Synergy Pharmaceuticals Files New Drug Application for Plecanatide in Chronic Idiopathic Constipation | 116 | 1 |
| Jan 19, 2016: Synthetic Biologics Reports Positive Topline Data from Second Phase 2 Clinical Trial of SYN-010 in Patients with Irritable Bowel Syndrome with Constipation (IBS-C) | 117 | 1 |
| Dec 08, 2015: Synthetic Biologics' SYN-010 Lowered Breath Methane and Improved Stool Frequency in a Phase 2 Four Week Study in Patients with Irritable Bowel Syndrome with Constipation (IBS-C) | 118 | 2 |
| Appendix | 120 | 2 |
| Methodology | 120 | 1 |
| Coverage | 120 | 1 |
| Secondary Research | 120 | 1 |
| Primary Research | 120 | 1 |
| Expert Panel Validation | 120 | 1 |
| Contact Us | 120 | 1 |
| Disclaimer | 121 | 1 |